KIF2A

Across TCGA pan-cancer cohorts, KIF2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KIF2A data layer compared with 31 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher KIF2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIF2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, UCEC, and BLCA are the cancer types where KIF2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.052	0.567	<.001	36	view →
UCEC	DFS	Median	All	0.972	0.828	.019	10	view →
BLCA	OS	Median	III,IV	0.182	0.579	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KIF2A–MESO (OS)

Open the MESO breakdown →